Ray tracing and IOL modelling in AMD patients

Video

Dr Uwe Oberheide discusses the key findings of his virtual ARVO 2021 presentation on modelling of IOLs for patients with AMD by ray tracing.

Dr Uwe Oberheide, of the University of Applied Sciences, Cologne, Germany, discusses the key findings from his virtual ARVO 2021 presentation on modelling of intraocular lenses (IOLs) for patients with age-related macular degeneration (AMD) by ray tracing.

See more ARVO content

Recent Videos
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Related Content
A syringe against a multicolor background, with a drip of liquid at the end of the needle. Image credit: ©iloli – stock.adobe.com

European Commission approves aflibercept biosimilar OPUVIZ (previously SB15) from Samsung Bioepis

Sydney M Crago
November 20th 2024
Article

OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

The FDA logo on a laptop computer. Image credit: ©monticellllo – stock.adobe.com

US FDA issues Complete Response Letter for avacincaptad pegol (Izervay, Astellas Pharma Inc)

Hattie Hayes;Jordana Joy
November 19th 2024
Article

The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An eye with digitally-rendered transparent DNA strands in front of it. Image credit: ©kittyfly – stock.adobe.com

US FDA clears investigational new drug application for CRISPR/Cas13 RNA-editing therapy

Sydney M Crago
November 12th 2024
Article

HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration

A sun sits on a horizon, over the clouds. Image by Jennifer Toomey/MJH Life Sciences using AI

Zooming in on geographic atrophy with OCT-based AI

By Lynda Charters; Reviewed by Ursula Schmidt-Erfurth, MD
November 11th 2024
Article

New analysis brings disease progression and therapeutics into focus

© 2024 MJH Life Sciences

All rights reserved.